Quarterly report [Sections 13 or 15(d)]

Asset Purchase and Merger Agreements - Checkpoint Transaction (Details)

v3.26.3
Asset Purchase and Merger Agreements - Checkpoint Transaction (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Asset Purchase and Merger Agreements          
Gain from deconsolidation of subsidiary   $ 104   $ 186 $ 27,127
Royalty revenue   234 $ 606 1,229 2,010
Checkpoint Merger          
Asset Purchase and Merger Agreements          
Proceeds from sale of subsidiary interests         $ 28,000
Checkpoint Merger          
Asset Purchase and Merger Agreements          
Milestone paid       0  
Checkpoint Merger | Checkpoint Merger | Sun Pharmaceutical Industries, Inc.          
Asset Purchase and Merger Agreements          
Stock purchase, price per share $ 4.1        
Maximum contingent consideration per each outstanding share $ 0.7        
Checkpoint Merger | Royalty revenue          
Asset Purchase and Merger Agreements          
Percentage of royalty on future net sales 2.50%        
Royalty revenue   $ 100   $ 200